Carl Zeiss Meditec has donated its latest generation optical biometry device to the Indigenous Diabetes Eyes and Screening (IDEAS) Van. Read more
New Specsavers report shows impact of eye health strategies
Specsavers’ latest snapshot into Australian eye health has revealed referrals for eye disease are soaring to unprecedented levels thanks to the systematic use of imaging technology and ophthalmology-led education, as well as other clinical interventions. Read more
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of Lucentis and Eylea to major global markets, including Australia. Read more
George & Matilda recognised for outstanding growth
For the second year in a row George & Matilda Eyecare has been recognised with top honours at the Australian Growth Company Awards. Read more
German manufacturer licenses BHVI algorithms for new device
The Brien Holden Vision Institute (BHVI) has signed a licensing agreement that will see its algorithms for tracking and estimating refractive error incorporated into a world-first instrument for myopia management. Read more
Australian College of Optometry extends clinic network
The Australian College of Optometry (ACO) has established a public health optometry clinic in a new state responding to unmet eyecare needs in both the general population and disadvantaged communities. Read more
Optometry Giving Sight establishes new board
International charity Optometry Giving Sight (OGS) has announced a new board of directors who will steer the organisation towards new priorities. Read more
Top alumni award presented to Fred Hollows CEO
The Fred Hollows Foundation’s CEO Mr Ian Wishart has been awarded the 2019 Chancellor’s Alumni Award from the University of Canberra in recognition of his contributions to the international humanitarian sector. Read more
FDA clears Novartis’ new treatment for nAMD
Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more
Perth partnership targets childhood blindness and $1 billion market
The Lions Eye Institute (LEI) has signed a commercial partnership that will combine its antisense gene therapy for a leading cause of childhood blindness with a new Australian-developed drug delivery platform. Read more